Position in FATE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$415,005
+$188,729 QoQ
Shares Held
153,706
-18.5% QoQ
Ownership
0.128%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#47
of 156 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority
Sole 85%
Shared 0%
None 15%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Derivatives in FATE
reported options exposure · as of Jun 30, 2022CallValue
$123,900
CallShares
5,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026BANK OF AMERICA CORP /DE/ holds $10,144,297,346 across 338 Biotechnology names. FATE ranks #252 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,039,178 | $1,509,650,884 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,291,053 | $805,023,185 | |
| 3 | CYTK |
Cytokinetics Inc
|
4,635,709 | $394,916,048 | |
| 4 | ARGX |
Argenx SE
|
400,234 | $371,325,094 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
994,476 | $299,367,107 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,136,091 | $273,763,844 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
4,568,341 | $259,527,450 | |
| 8 | RPRX |
Royalty Pharma plc
|
4,149,422 | $232,658,090 |
All Filings in FATE
Export CSV
28 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $415,005 | 153,706 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $226,276 | 188,564 | Shares | Defined | 2026-05-18 | |
| 2025-12-31 | $148,083 | 151,107 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $184,654 | 146,553 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $136,783 | 122,130 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $306,868 | 388,443 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $501,811 | 304,129 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $2,989,681 | 854,195 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $6,513,199 | 1,985,732 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $14,091,154 | 1,919,776 | Shares | Defined | 2024-05-15 | |
| 2023-12-31 | $2,270,193 | 607,004 | Shares | Defined | 2024-02-14 | |
| 2023-09-30 | $407,192 | 192,072 | Shares | Defined | 2023-11-14 | |
| 2023-06-30 | $5,816,280 | 1,221,908 | Shares | Defined | 2023-08-14 | |
| 2023-03-31 | $12,280,814 | 2,154,529 | Shares | Defined | 2023-05-12 | |
| 2022-12-31 | $4,821,776 | 477,877 | Shares | Defined | 2023-02-10 | |
| 2022-09-30 | $7,506,115 | 334,945 | Shares | Defined | 2022-11-14 | |
| 2022-06-30 | $123,900 | 5,000 | Call | Defined | 2022-08-12 | |
| 2022-06-30 | $7,888,438 | 318,339 | Shares | Defined | 2022-08-12 | |
| 2022-03-31 | $12,565,780 | 324,111 | Shares | Defined | 2022-05-16 | |
| 2022-03-31 | $170,588 | 4,400 | Call | Defined | 2022-05-16 | |
| 2021-12-31 | $22,420,853 | 383,197 | Shares | Defined | 2022-02-08 | |
| 2021-09-30 | $14,294,201 | 241,171 | Shares | Defined | 2021-11-15 | |
| 2021-06-30 | $23,007,331 | 265,092 | Shares | Defined | 2021-09-13 | |
| 2021-03-31 | $18,175,770 | 220,446 | Shares | Defined | 2021-05-14 | |
| 2020-12-31 | $14,120,244 | 155,287 | Shares | Defined | 2021-02-10 | |
| 2020-09-30 | $3,853,785 | 96,417 | Shares | Defined | 2020-11-13 | |
| 2020-06-30 | $4,207,022 | 122,618 | Shares | Defined | 2020-08-14 | |
| 2020-03-31 | $3,154,329 | 142,023 | Shares | Defined | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||